N@N

Medtronic to Release New Clinical Data on Unrivaled Portfolio of Interventional Devices at EuroPCR

_{//health-fitness.news-articles.net/content/2011/ .. tfolio-of-interventional-devices-at-europcr.html}
^{Published in Health and Fitness on Thursday, May 12th 2011 at 4:15 GMT by Market Wire}  

MINNEAPOLIS--([ BUSINESS WIRE ])--New clinical data on a range of innovative medical devices from Medtronic, Inc. (NYSE: MDT), to treat cardiac and vascular diseases a" from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease a" will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17a"20.

"Medtronic has never been better positioned to offer such an extensive array of technologies to address the difficult challenges that clinicians face every day"

aMedtronic has never been better positioned to offer such an extensive array of technologies to address the difficult challenges that clinicians face every day,a said Michael J. Coyle, executive vice president of Medtronic, Inc., and president of the Cardiac and Vascular Group at Medtronic. aEuroPCR presents an excellent opportunity to share some of the latest clinical evidence on these technologies, which will be discussed in scientific sessions and showcased at the highly interactive Medtronic booth.a

Sessions of interest from the aCoronary and structural heart diseasea and aEndovasculara programmes are listed below, all in Central European Summer Time (CEST):

Tuesday 17 May

10:00a"11:00 / Welcome and Live Demonstration from Frankfurt (Main Arena)

• 10:10a"10:30 /aRenal denervation: a new treatment option in hypertension and beyond?a�

12:00a"14:25 / Whata�s new in endovascular interventions? Late breaking trials (Room Maillot)

• 12:15a"12:23 / aDESERVE study: diffusion weighted - magnetic resonance imaging based evaluation of the effectiveness of endovascular clamping during carotid artery stenting with the Mo.Ma device. Results from a prospective, multicentre studya�
• 12:43a"12:51 /aMARIS - 1,000 patient superficial femoral artery registrya�
• 12:57a"13:05 / aDrug-eluting balloon for the treatment of femoro-popliteal arterial disease: mid-term results from a multicentre Italian registrya�

14:00a"15:30 / The role of the interventional cardiologist from the coronary to the renal arteries (Room 342AB)

16:30a"18:00 / Quality of life and neurocognitive function after TAVI (Room 353)

• 17:02a"17:11 / aHealth-related quality-of-life shows sustained improvement with transcatheter aortic valvea�

Wednesday 18 May

12:00a"13:30 / Which DES for diabetics? (Room 242B)

• 12:19a"12:28 / RESOLUTE Pooled Diabetics: aTreatment with the Resolute Zotarolimus-eluting stent in subjects with diabetes mellitus: pooled analysis from the Resolute clinical programmea�
• 12:32a"12:41 / aClinical outcomes in diabetic and non diabetic patients treated with Endeavor Resolute Zotarolimus eluting-stent: a multicentre Italian observational studya�

15:00a"16:30 / Renal denervation therapy (Room 342AB)

Thursday 19 May

09:00a"10:30 / Management of arterial access in TAVI (Room 341)

• 09:32a"09:41 / a1-year results of the subclavian access for TAVI with the CoreValve bioprosthesis in 132 consecutive patientsa�

16:30a"18:00 / Risk of stent thrombosis and new generation DES (Room 353)

• 17:41a"17:50 / aSafety of dual antiplatelet therapy interruption after Resolute stent implantation: an Italian multicentre observational evaluationa�

Friday 20 May

09:10a"12:10 / Late-Breaking Registries and Trial Updates (Room 342AB)

• 09:10a"09:20 / RESOLUTE Pooled Safety: aPooled analysis of the Resolute programme clinical safety resultsa�
• 12:00a"12:08 / aA weighted meta-analysis of early and late clinical outcomes after CoreValve percutaneous aortic valve replacement in seven national registriesa�

The CoreValve System, IN.PACT DEB, Resolute DES and Symplicity Catheter System are all investigational devices in the United States, where their use is limited by U.S. law to clinical studies approved by the FDA.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

ABOUT MEDTRONIC

Medtronic, Inc. ([ www.medtronic.com ]), headquartered in Minneapolis, is the global leader in medical technology a" alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronica�s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.